Five Prime looks to turn a corner
Survival data with bemarituzumab see the company erase half of the past three years’ losses.
Pharma news over the Christmas period 2019
If the recent performance of biotech stocks prompted you to pull down the shutters until the New Year celebrations subsided here’s what you might have missed.